摘要:
关键词:宫颈上皮内瘤样病变;子宫颈;高危型人乳头瘤病毒阳性;p16/Ki-67双染;实验性研究
Abstract:
Key words: Cervical intraepithelial neoplasia;Ervix Uteri;HR-HPV positive;p16/Ki-67 dual staining;Experiment study
发表日期:2020/2
引用本文:
参考文献:
[1]ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.[2]WHO. Screening as well as vaccination is essential in the fight against cervical cancer[EB/OL].[2019-09-01]. http://www.who.int/reproductivehealth/topics/cancers/fight-cervical-cancer/en/.
[3]赵方辉,章文华,潘秦镜,等.宫颈癌多种筛查方案的研究[J].中华肿瘤杂志,2010,32(6):420-424. DOI: 10.3760/cma.j.issn.0253-3766.2010.06.005.
[4]ShanmugasundaramS, YouJ. Targeting persistent human papillomavirus infection[J]. Viruses, 2017, 9(8): 229. DOI: 10.3390/v9080229.
[5]WentzensenN, SchiffmanM, PalmerT, et al. Triage of HPV positive women in cervical cancer screening[J]. J Clin Virol, 2016,76Suppl 1:S49-49S55. DOI: 10.1016/j.jcv.2015.11.015.
[6]董丽,胡尚英,张倩,等.山西省宫颈癌筛查队列中人乳头瘤病毒基因型别分布10年动态变化规律研究[J].中华流行病学杂志,2017,38(1):20-25. DOI: 10.3760/cma.j.issn.0254-6450.2017.01.004.
[7]赵方辉,陈俊峰,高晓虹,等.子宫颈癌筛查及早诊早治方案的绩效和卫生经济学评价[J].中华肿瘤杂志,2012,34(8):632-636. DOI: 10.3760/cma.j.issn.0253-3766.2012.08.017.
[8]赵雪莲,热米拉·热扎克,胡尚英,等.高危型HPV DNA单独检测及与薄层液基细胞学联合筛查对宫颈癌及宫颈高度病变的筛查效果比较[J].中华预防医学杂志,2018,52(5):469-474. DOI: 10.3760/cma.j.issn.0253-9624.2018.05.004.
[9]WentzensenN, von Knebel DoeberitzM. Biomarkers in cervical cancer screening[J]. Dis Markers, 2007,23(4):315-330. DOI: 10.1155/2007/678793.
[10]GoodmanA. HPV testing as a screen for cervical cancer[J]. BMJ, 2015,350:h2372. DOI: 10.1136/bmj.h2372.
[11]陈汶,于露露,王红,等. cobas4800高危型人乳头瘤病毒检测技术在子宫颈癌前病变筛查和细胞学转诊中的应用[J].中华肿瘤杂志,2012,34(7):543-548. DOI: 10.3760/cma.j.issn.0253-3766.2012.07.014.
[12]潘秦镜,李凌,张询,等.液基细胞学筛查宫颈癌的研究[J].中华肿瘤杂志, 2001,23(4):309-312.DOI:10.3760/j.issn:0253-3766.2001.04.012.
[13]王海瑞,廖光东,陈汶,等. p16/Ki-67免疫细胞化学双染在宫颈癌筛查中的应用价值[J].中华肿瘤杂志,2017,39(8):636-640. DOI: 10.3760/cma.j.issn.0253-3766.2017.08.015.
[14]中华预防医学会疫苗与免疫分会.子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J].中华预防医学杂志,2019,53(8):761-803. DOI: 10.3760/cma.j.issn.0253?9624.2019.08.001.
[15]WangHR, LiYC, GuoHQ, et al. A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening[J]. Oncotarget, 2017,8(48):83890-83899. DOI: 10.18632/oncotarget.19870.
[16]YuLL, ChenW, LeiXQ, et al. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China[J]. Oncotarget, 2016,7(16):21181-21189. DOI: 10.18632/oncotarget.8307.
[17]SilvaDC, Gon?alvesAK, CobucciRN, et al. Immunohistochemical expression of p16, Ki-67 and p53 in cervical lesions -A systematic review[J]. Pathol Res Pract, 2017,213(7):723-729. DOI: 10.1016/j.prp.2017.03.003.
[18]ScholzenT, GerdesJ. The Ki-67 protein: from the known and the unknown[J]. J Cell Physiol, 2000,182(3):311-322. DOI: 10.1002/(SICI)1097-4652(200003)182∶3<311::AID-JCP1>3.0.CO;2-9.
[19]LiaoGD, SellorsJW, SunHK, et al. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China[J]. Int J Cancer, 2014,134(7):1715-1724. DOI: 10.1002/ijc.28485.
[20]高燕,岳文涛.人乳头瘤病毒致癌机制及相关疫苗研究进展[J].国际病毒学杂志,2019,26(1):69-72. DOI: 10.3760/cma.j.issn.1673-4092.2019.01.020.
[21]TjalmaW. Diagnostic performance of dual-staining cytology for cervical cancer screening: a systematic literature review[J]. Eur J Obstet Gynecol Reprod Biol, 2017,210:275-280. DOI: 10.1016/j.ejogrb.2017.01.009.
[22]IkenbergH, BergeronC, SchmidtD, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study[J]. J Natl Cancer Inst, 2013,105(20):1550-1557. DOI: 10.1093/jnci/djt235.
[23]StanczukGA, BaxterGJ, CurrieH, et al. Defining optimal triage strategies for hrHPV screen-positive women-an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 Cytoimmunochemistry[J]. Cancer Epidemiol Biomarkers Prev, 2017,26(11):1629-1635. DOI: 10.1158/1055-9965.EPI-17-0534.
[24]EbischRM, van der HorstJ, HermsenM, et al. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women[J]. Mod Pathol, 2017,30(7):1021-1031. DOI: 10.1038/modpathol.2017.16.
[25]OuhYT, MinKJ, ChoHW, et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016[J]. J Gynecol Oncol, 2018,29(1):e14. DOI: 10.3802/jgo.2018.29.e14.
[26]DunneEF, UngerER, SternbergM, et al. Prevalence of HPV infection among females in the United States[J]. JAMA, 2007,297(8):813-819. DOI: 10.1001/jama.297.8.813.
[27]MarkowitzLE, HaririS, LinC, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010[J]. J Infect Dis, 2013,208(3):385-393. DOI: 10.1093/infdis/jit192.
[28]WentzensenN, FettermanB, CastlePE, et al. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women[J]. J Natl Cancer Inst, 2015,107(12):djv257. DOI: 10.1093/jnci/djv257.
[29]WrightTCJr, BehrensCM, Ranger-MooreJ, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial[J]. Gynecol Oncol, 2017,144(1):51-56. DOI: 10.1016/j.ygyno.2016.10.031.
[30]周爱芬,张斌,罗欣,等.武汉市17万农村妇女宫颈癌筛查方法效果评价[J].中国妇幼保健,2013,28(8):1238-1240. DOI: 10.7620/zgfybj.j.issn.1001-4411.2013.28.08.
用户评论 0条